<DOC>
	<DOCNO>NCT01185236</DOCNO>
	<brief_summary>A single center , open label , randomize , clinical trial compare ApoB/ApoA ratio Vytorin 10/20mg v atorvastatin 20mg treatment . DM2 patient screen inclusion criterion . Patients ( n=66 arm ) randomize either Ezetimibe/simvastatin 10/20mg atorvastatin 20mg 4 week washout TLC period . Primary secondary endpoint assess week 12 . Primary endpoint : 1 ) change ApoB/ApoA ratio week 12 . Secondary endpoint : 1 . Change lipid parameter ( TC , LDL-C , HDL-C , TG , apoB 48 ) week 12 . 2 . Change HbA1C week 12 . 3 . Change HOMA index week 12 - HOMA = [ Fasting insulin ( mIU/L ) Ã— Fasting glucose ( mmol/L ) ] / 22.5 4 . Change hsCRP week 12 5 . Safety assessment Hypotheses : - Three month treatment Vytorin 10/20mg superior atorvastatin 20mg ApoB/ApoA ratio . - In DM patient , Ezetimibe/Simvastatin Combination well-tolerated .</brief_summary>
	<brief_title>Study Compare Effect Vytorin ( Simvastatin/Ezetimibe ) 10/20mg Versus Atorvastatin 20mg ApoB/ApoA1 Ratio Subjects With Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>1 . Type 2 DM 2 . Hypercholesterolemia ( baseline screen LDLC &gt; 100 mg/dL ) 3 . In case medication , stable dos oral hypoglycemic agent least three month 4 . HbA1c &lt; 8.5 % 5 . Age : 2080 1 . Chronic renal failure : creatinine &gt; 3.0 mg/dL 2 . Serious liver disease ( &gt; x3 LFT UNL ) 3 . Congestive heart failure 4 . Stroke MI/coronary intervention precede 3 month . 5 . CK &gt; x 2.5 UNL 6 . Unstable hypo/hyperthyroidism 7 . Pregnant/lactating woman , woman intend become pregnant 8 . Subject clinically significant condition situation , opinion investigator , would interfere study evaluation optimal participation study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Diabetes mellitus</keyword>
</DOC>